Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$3.19
+2.9%
$2.88
$2.01
$5.64
$212.22M1.811.14 million shs687,598 shs
MediWound Ltd. stock logo
MDWD
MediWound
$21.08
-1.1%
$17.68
$12.78
$24.00
$227.83M0.391,321 shs62,707 shs
Rezolute, Inc. stock logo
RZLT
Rezolute
$3.95
+3.1%
$3.31
$2.22
$6.19
$239.11M1.01590,298 shs799,038 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.99
-9.5%
$1.97
$1.14
$12.45
$61.64M1.74366,705 shs198,200 shs
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+2.90%+10.00%+8.14%-21.43%-1.85%
MediWound Ltd. stock logo
MDWD
MediWound
-1.13%+5.98%+15.25%+29.88%+18.49%
Rezolute, Inc. stock logo
RZLT
Rezolute
+3.13%-1.50%+5.05%-6.84%+7.05%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-9.32%-9.73%+4.45%-25.56%-83.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
1.6557 of 5 stars
3.50.00.00.04.30.00.6
MediWound Ltd. stock logo
MDWD
MediWound
1.549 of 5 stars
3.51.00.00.02.00.80.6
Rezolute, Inc. stock logo
RZLT
Rezolute
2.8144 of 5 stars
3.62.00.00.03.34.20.0
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1.0419 of 5 stars
3.51.00.00.01.90.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
3.00
Buy$12.00276.18% Upside
MediWound Ltd. stock logo
MDWD
MediWound
3.00
Buy$31.2548.24% Upside
Rezolute, Inc. stock logo
RZLT
Rezolute
3.14
Buy$12.14207.41% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
3.00
Buy$16.60734.17% Upside

Current Analyst Ratings Breakdown

Latest SKYE, MDWD, RZLT, and CRDF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
MediWound Ltd. stock logo
MDWD
MediWound
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$25.00 ➝ $31.00
5/20/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/14/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$12.00
5/9/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$17.00 ➝ $18.00
5/2/2025
MediWound Ltd. stock logo
MDWD
MediWound
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00
4/28/2025
Rezolute, Inc. stock logo
RZLT
Rezolute
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
3/21/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $14.00
3/21/2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/20/2025
MediWound Ltd. stock logo
MDWD
MediWound
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
2/28/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $17.00
2/28/2025
MediWound Ltd. stock logo
MDWD
MediWound
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$39.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$587K361.53N/AN/A$1.56 per share2.04
MediWound Ltd. stock logo
MDWD
MediWound
$19.21M11.86N/AN/A$3.43 per share6.15
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/A$1.65 per shareN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A($0.17) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$41.44M-$0.92N/AN/AN/A-6,238.17%-73.97%-60.40%8/14/2025 (Estimated)
MediWound Ltd. stock logo
MDWD
MediWound
-$6.72M-$2.09N/AN/AN/A-142.29%-82.17%-33.67%8/13/2025 (Estimated)
Rezolute, Inc. stock logo
RZLT
Rezolute
-$68.46M-$1.15N/AN/AN/AN/A-70.27%-62.41%N/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/A

Latest SKYE, MDWD, RZLT, and CRDF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
MediWound Ltd. stock logo
MDWD
MediWound
-$0.65-$0.07+$0.58-$0.07$5.20 million$3.96 million
5/13/2025Q3 2025
Rezolute, Inc. stock logo
RZLT
Rezolute
-$0.22-$0.27-$0.05-$0.27N/AN/A
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
5/8/2025Q1 2025
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.31-$0.28+$0.03-$0.28N/AN/A
3/20/2025Q4 2024
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.30-$0.24+$0.06-$0.24N/AN/A
3/19/2025Q4 2024
MediWound Ltd. stock logo
MDWD
MediWound
-$0.59-$0.36+$0.23-$0.36$5.79 million$5.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
MediWound Ltd. stock logo
MDWD
MediWound
N/AN/AN/AN/AN/A
Rezolute, Inc. stock logo
RZLT
Rezolute
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.74
4.74
MediWound Ltd. stock logo
MDWD
MediWound
N/A
2.11
1.99
Rezolute, Inc. stock logo
RZLT
Rezolute
N/A
9.30
9.30
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
14.19
14.19

Institutional Ownership

CompanyInstitutional Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
MediWound Ltd. stock logo
MDWD
MediWound
46.83%
Rezolute, Inc. stock logo
RZLT
Rezolute
82.97%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
MediWound Ltd. stock logo
MDWD
MediWound
9.20%
Rezolute, Inc. stock logo
RZLT
Rezolute
18.39%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
4.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million47.15 millionOptionable
MediWound Ltd. stock logo
MDWD
MediWound
8010.81 million9.79 millionOptionable
Rezolute, Inc. stock logo
RZLT
Rezolute
4060.54 million49.40 millionOptionable
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
1130.98 million29.43 millionOptionable

Recent News About These Companies

Leo Miller: Page 6

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$3.19 +0.09 (+2.90%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$3.23 +0.04 (+1.25%)
As of 05/28/2025 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

MediWound stock logo

MediWound NASDAQ:MDWD

$21.08 -0.24 (-1.13%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$21.08 0.00 (-0.02%)
As of 05/28/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Rezolute stock logo

Rezolute NASDAQ:RZLT

$3.95 +0.12 (+3.13%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$4.04 +0.09 (+2.41%)
As of 05/28/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$1.99 -0.21 (-9.55%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$2.01 +0.02 (+0.80%)
As of 05/28/2025 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.